Stock Detail
RIGEL PHARMACEUTICALS INC
Drug Manufacturers Major
RIGL @ Yahoo Finance | RIGL Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $6.98 | $7.26 | $-0.33 | -4.51% | 0.00 | $7.31 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $7.20 | $6.97 | 286,835 | 497.28M | 387,189.5 | -5.33 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 7.36 | 7.17 | 7.07 | 6.88 | 6.78 |
Stock Profile
Rigel Pharmaceuticals, Inc. engages in the discovery and development of small-molecule product candidates for the treatment of unmet medical needs. It has three product development programs, such as allergy/asthma, rheumatoid arthritis, and cancer. The company develops R112, which is in Phase II clinical trial for the treatment of allergic rhinitis; and R406/788 that is in Phase I clinical study for the treatment of rheumatoid arthritis. Rigel's another product candidate R406 is in preclinical studies, which is an oral Syk kinase inhibitor that blocked the activation of mast cells and B cells that promote the swelling and inflammatory response. It has collaboration agreements with Janssen Pharmaceutica N.V.; Pfizer, Inc.; Novartis Pharma AG; Daiichi Pharmaceuticals Co., Ltd.; and Merck and Co., Inc. Rigel was incorporated in 1996 and is based in South San Francisco, California.